Skip to content

Homeopathic treatment of eczema

Comparative effectiveness of centesimal and 50 millesimal potencies in treatment of atopic dermatitis in adults: An open, randomized trial

Status
Recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/08/044844
Enrollment
60
Registered
2022-08-23
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

Intervention1: Individualized homeopathic medicines in LM (50 millesimal) potencies: In 50-millesimal scale, a single-medicated cane sugar globule of poppy seed size (no. 10) will be dissolved in 80 m
16 doses to be marked on the vial
each dose of 5 mL will be taken after 10 uniformly forceful downward strokes to the vial in 45 mL normal water in a clean cup, to stir well, to take 5 mL of this liquid orally and to discard rest of t

Sponsors

D N De Homoeopathic Medical College Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed cases of AD (ICD-10-CM code L20.9) as per UK diagnostic criteria with a minimum duration of suffering of 3 months 2. PO-SCORAD values more than 10 3. Age: 18-65 years 4. Participants of either sex 5. Literate patients; ability to read Bengali and/or English 6. Patients giving written informed consent to participate 7. Patients already undergoing treatment for AD were planned to be recruited on completely stopping the medicines and after wash-out phase of 1 month

Exclusion criteria

Exclusion criteria: 1. Severe and disseminated forms of atopic dermatitis 2. Vulnerable population ââ?¬â?? unconscious, ambulatory, too sick for consultation, differently abled, terminally ill or critically ill patients, institutionalized subjects, mentally incompetent people 3. Diagnosed cases of unstable psychiatric or uncontrolled or life-threatening systemic illness affecting quality of life or any organ failure 4. Tobacco chewing and/or smoking or any other form(s) of substance abuse and/or dependence 5. Self-reported immune-compromised states 6. Pregnant and lactating women, puerperal mothers 7. Patients already undergoing homeopathic treatment for any chronic disease within last 6 months

Design outcomes

Primary

MeasureTime frame
Patient-oriented scoring for atopic dermatitis (PO-SCORAD)Timepoint: At baseline, every month, up to 6 months

Secondary

MeasureTime frame
Atopic dermatitis burden scale for adults (ADBSA)Timepoint: At baseline, every month, up to 6 months;Dermatological life quality index (DLQI)Timepoint: At baseline, every month, up to 6 months

Countries

India

Contacts

Public ContactProf Dr Mohan Giri

D N De Homoeopathic Medical College & Hospital

giri.drmohan@gmail.com9433904265

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026